David Grayzel, M.D.
David Grayzel, M.D., is co-founder of Surface Oncology and a partner at Atlas Venture. Since joining Atlas Venture in 2010, Dr. Grayzel co-founded and served as chief executive officer of Arteaus Therapeutics, LLC, which was acquired by Eli Lilly in 2014, as well as co-founder and chief executive officer of Annovation Biopharma Inc., which was acquired by The Medicines Company in early 2015. He is currently a co-founder and acting chief executive officer of Ataxion, founding board member of Delinia and co-founder of Quartet Medicine. Previously, he was a member of the executive team at Infinity Pharmaceuticals and was responsible for all clinical research activities as the head of clinical development and medical affairs. Dr. Grayzel obtained his bachelor’s degree from Stanford University, his medical degree from Harvard Medical School and completed his internship and residency training in internal medicine at Massachusetts General Hospital. David serves on the board of Acera: The Massachusetts School for Science, Creativity, and Leadership, a STEM focused K-8 school, which he and his wife Courtney started in 2009. David also serves as an advisor to Memorial Sloan Kettering Cancer Center’s Technology Development Fund, a member of the Tri-Institutional TDI Antibody SAB and founding member of the American Heart Association’s One Brave Idea team.